Change the Question Your Clients Ask About PBMs
From Pricing Comparisons to Structural Accountability
Real-time independent routing gives benefits consultants a structural standard that moves the conversation beyond pricing, rebates, and service levels. Can the PBM demonstrate - through an independent party - that each high-cost prescription was routed to the lowest net cost? If not, there is a gap your client should know about.
Request a ConversationEvery PBM Evaluation Has the Same Blind Spot
The data you use to evaluate PBMs comes from the PBM being evaluated.
Self-Reported Data
Pricing analyses, rebate guarantees, and utilization reports are all produced by the PBM you are evaluating. The entity making routing decisions is the same entity reporting on whether those decisions were optimal. No independent party is in the loop.
Aggregate Reporting
PBM reports show totals - total spend, total rebates, overall generic fill rates. They do not show a decision-level record for each prescription: which channels were evaluated, what the actual net cost was at each, and why the winning channel was selected.
Fiduciary Exposure
Your clients face personal fiduciary liability for drug benefit decisions under ERISA and the CAA. Recommending a PBM program without independent verification of routing decisions leaves a documentation gap that regulators and auditors are increasingly focused on.
Same Conversation Every Cycle
Every renewal, you compare PBM proposals on price, rebates, and service. The proposals look similar. The guarantees are structured similarly. You are competing on the same axis as every other consultant - and your clients are not getting structurally better outcomes.
Real-time independent routing changes the question from ‘Is this a good deal?’ to ‘Does this have integrity?’
What You Can Offer Clients
A structural standard that differentiates your advisory practice
Real-Time Independent Routing
Alongside Any PBM
Recommend ApalyRx as a routing layer that works alongside your client’s current PBM. Their high-cost prescriptions get real-time lowest-net-cost routing across all channels - PBM specialty, PBM mail, manufacturer-direct, and independent pharmacy - with decision-level documentation for every script.
Fiduciary Protection
Documentation Your Clients Need
In an environment of increasing fiduciary scrutiny, recommending independent routing and decision-level documentation demonstrates your commitment to your client’s best interest. Every routing decision is recorded - channels compared, rules applied, rationale documented. This is the proof fiduciaries need.
Practice Differentiation
Define the New Standard
Be the consultant who introduces real-time independent routing to your market. The first consultants to adopt this approach will define how their clients evaluate pharmacy benefits - shifting the conversation from pricing comparisons to structural integrity.
Better Client Outcomes
Measurable Impact
Independent routing across all channels consistently identifies lower-cost options for high-cost medications. Your clients see real savings - typically 20-40% on in-scope drugs - with transparent, pass-through economics and no hidden spread. The results speak for themselves.
Your recommendation. Their savings. Independent proof it worked.
Use the Drug Benefit Integrity Framework
The DBI Framework is a free, one-page evaluation tool with five binary requirements. Use it in RFP evaluations, PBM reviews, and strategy meetings. It gives you a structured, defensible way to evaluate whether a pharmacy benefit program has structural integrity - and to document that evaluation for your client's fiduciary records.
Evaluate
Score your client’s current PBM arrangement against the five DBI requirements. Any ‘No’ identifies a structural verification gap.
Compare
Use the framework in your next PBM review or RFP evaluation. Ask every finalist: can you demonstrate independent routing and decision-level documentation?
Document
A completed DBI framework evaluation provides fiduciary evidence that drug benefit decisions were assessed against an independent structural standard.
Share
Forward the framework to plan fiduciaries, HR leaders, and CFOs. The more people asking the question, the faster independent verification becomes expected.
Why Consultants Are Moving First
Regulatory Tailwinds
The CAA, FTC enforcement, and DOL proposed rules are all pushing toward independent verification of drug benefit decisions. Consultants who introduce these concepts now are positioned as forward-thinking advisors - not reactive order-takers.
Client Demand
Employers are hearing about independent routing from industry coverage, peer networks, and other advisors. The consultants who bring the conversation to their clients first own the relationship. Those who wait will be responding to questions they did not initiate.
Competitive Moat
Once you introduce the DBI standard to your clients, it becomes part of how they evaluate PBMs going forward. You are not selling a point solution - you are establishing a structural expectation that keeps you at the center of every renewal conversation.
Frequently Asked Questions
No. ApalyRx works alongside any PBM. The PBM continues to manage formularies, negotiate contracts, and administer the benefit. ApalyRx adds an independent routing layer for high-cost medications - typically about 30 drugs representing 40% or more of pharmacy spend. The rest of the benefit stays exactly as it is.
Frame it as a fiduciary best practice: independent verification of high-cost drug routing decisions. Your client is not replacing their PBM - they are adding a layer of accountability and documentation that strengthens their program and protects their fiduciary position. If their PBM’s routing is already optimal, the documentation proves it.
Many PBMs are choosing to offer ApalyRx as part of their own program - independent routing strengthens their client relationships. Position it to the PBM as a competitive advantage: their pharmacies are always in the evaluation, and when they win, there is independent proof. PBMs that embrace this proactively are in a stronger position than those that resist it.
You introduce the concept and make the recommendation. ApalyRx handles all implementation - technical integration, member experience, operations, and reporting. You receive program-level reporting to share with your client. There is no operational burden on your team.
ApalyRx programs are scoped to a targeted set of high-cost drugs and operate alongside the existing PBM relationship. Your compensation arrangements with the PBM are between you and the PBM. ApalyRx does not interfere with those arrangements. We can discuss how to structure the engagement so all parties benefit.
Yes. The DBI Framework is a free, one-page evaluation tool available at drugbenefitintegrity.com. You can include the five DBI requirements in any RFP or PBM evaluation. Ask every finalist whether they can demonstrate independent routing, decision-level documentation, and structural independence from dispensing channels.
Independent routing across all channels consistently identifies lower-cost options for high-cost medications - typically 20-40% savings on in-scope drugs. Clients also receive decision-level documentation for every prescription, fiduciary-grade reporting, and an improved member experience with concierge support and home delivery.
Drug Benefit Integrity (DBI) is an independent industry standard with five structural requirements for ensuring pharmacy benefit decisions are made in the plan’s interest. ApalyRx is the only entity that meets all five. The DBI Framework gives you a structured, defensible way to evaluate any PBM program - and to document that evaluation for your client’s fiduciary records. Learn more at drugbenefitintegrity.com.
Bring Independent Routing to Your Clients
The First Consultants to Adopt This Will Define the Standard.
Tell us about your client base and how you approach PBM evaluations. We will show you how ApalyRx fits alongside your clients' existing programs - and how the DBI Framework can become part of your evaluation toolkit.
Request a Conversation